SOLVONIS THERAPEUTICS PLC financials
SOLVONIS THERAPEUTICS PLC
2138005PH7OJRCRPUD88 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | £0 | £0 |
| Administrative expenses | £3.0M | £1.1M |
| Operating profit (EBIT) | -£5.7M | -£1.4M |
| Finance costs | £0 | £64.0K |
| Profit before tax | -£5.7M | -£1.4M |
| Income tax expense | £0 | £0 |
| Profit for the year | -£5.7M | -£1.6M |
| — attributable to owners | -£5.7M | -£1.6M |
| Total comprehensive income | -£5.9M | -£1.5M |
| Per share | ||
| Basic EPS | £-0.00 | £-0.00 |
| Cash flow statement | ||
| Net cash from operating activities | -£3.3M | -£1.1M |
| Net cash from investing activities | £0 | -£337.0K |
| Net cash from financing activities | £4.2M | £2.1M |
| Net change in cash | £958.0K | £616.0K |
| Balance sheet | ||
| Total assets | £7.6M | £3.2M |
| Non-current assets | £5.7M | £2.4M |
| Current assets | £1.9M | £815.0K |
| Trade & other receivables | £198.0K | £58.0K |
| Cash & equivalents | £1.7M | £757.0K |
| Total equity | £6.2M | £3.1M |
| Non-current liabilities | £914.0K | £0 |
| Current liabilities | £480.0K | £119.0K |
| Trade & other payables | £480.0K | £119.0K |
| Derived metrics | ||
| Return on equity | -92.7% | -51.6% |
| Cash conversion ratio | 0.57× | 0.71× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade and Other Receivables | -£88.0K | £31.0K |
| Adjustments For Finance Costs | £0 | £64.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | £2.3M | £0 |
| Adjustments For Increase Decrease In Trade and Other Payables | -£501.0K | -£58.0K |
| Adjustments For Sharebased Payments | £559.0K | £317.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -£131.0K | £0 |
| Borrowings | £75.0K | £0 |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £0 | -£13.0K |
| Comprehensive Income Attributable To Owners of Parent | -£5.9M | -£1.6M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | £5.0K | -£14.0K |
| Employee Contributions | £559.0K | £317.0K |
| Expense From Cashsettled Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets | £559.0K | £317.0K |
| Foreign Exchange Gain | £98.0K | £0 |
| Impairment Loss | £2.3M | £0 |
| Increase Decrease Through Disposal of Subsidiary | — | -£109.0K |
| Increase Decrease Through Other Contributions By Owners | £9.0M | £2.6M |
| Intangible Assets Other Than Goodwill | £5.7M | £2.1M |
| Issue of Equity | £8.0M | £2.0M |
| Issued Capital | £6.7M | £2.2M |
| Liabilities | £1.4M | £119.0K |
| Net Assets Liabilities | £6.2M | £3.1M |
| Noncurrent Payables | £839.0K | £0 |
| Other Comprehensive Income | -£170.0K | £62.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation Other Than Translation of Foreign Operations | -£170.0K | £62.0K |
| Other Noncurrent Assets | £0 | £300.0K |
| Other Reserves | £2.5M | £2.5M |
| Payments For Share Issue Costs | £39.0K | £41.0K |
| Proceeds From Issue of Bonds Notes and Debentures | £0 | £200.0K |
| Proceeds From Issuing Shares | £4.3M | £1.9M |
| Profit Loss From Continuing Operations | -£5.7M | -£1.4M |
| Profit Loss From Discontinued Operations | £0 | -£143.0K |
| Purchase of Other Longterm Assets Classified As Investing Activities | £0 | £320.0K |
| Reserve of Exchange Differences On Translation | -£170.0K | £0 |
| Reserve of Sharebased Payments | £2.5M | £1.5M |
| Retained Earnings | -£16.3M | -£10.6M |
| Share Issue Related Cost | £39.0K | £41.0K |
| Share Premium | £10.9M | £7.4M |
Every line item above is a fact tagged in SOLVONIS THERAPEUTICS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.